P38 MAP kinase inhibitors

US8299073B2 · kind B2 · utility

Assignee

• RESPIVERT LTD. · GB

Inventors

• Kazuhiro Ito · London, GB
• Peter Strong · London, GB
• William Garth Rapeport · London, GB
• Peter John Murray · London, GB
• John King-Underwood · Pendock, GB
• Jonathan Gareth Williams · Nuneaton, GB
• Stuart Thomas Onions · Nottingham, GB
• Simon Christopher Hirst · Swansea, GB
• David Michel Adrien Taddei · Nottingham, GB
• Catherine Elisabeth Charron · London, GB

Key dates

• Filing date: Dec 11, 2009
• Grant date: Oct 30, 2012
• Expiry date: Dec 11, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of formula (I):or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.